For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Fesoterodine fumarate - Overactive bladder (adults)
PAD Profile : Fesoterodine fumarate - Overactive bladder (adults) Important
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Oxybutynin
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.
Fesoterodine is recommended as a 3rd line option in patients who require, and can tolerate, a more potent treatment.
Solifenacin is the 1st line treatment option.
Tolterodine immediate release tablets or Trospium are 2nd line options in patients for whom solifenacin is not suitable.
See Selection Tool for locally agreed OAB treatment options